ACRP CCRA CERTIFICATION SCRIPT
2026 QUESTIONS WITH SOLUTIONS
GRADED A+
◍ Elements of Protocol: Title and Cover Page.
Answer: The title of the IB and any relevant cover page information, such as
the study name, sponsor, and version number.
◍ Elements of Protocol: Table of Contents.
Answer: A list of sections and subsections contained within the IB.
◍ Elements of Protocol: Introduction.
Answer: A brief overview of the investigational product, including its
purpose and background information.
◍ Elements of Protocol: Study Objectives and Protocol.
Answer: A description of the ___________________ and an overview of the
clinical trial ___________________ .
◍ Elements of Protocol: Investigational Product Description.
Answer: Detailed information about the investigational product, including
its chemical composition, formulation, packaging, and storage requirements.
◍ Adverse Event (or Adverse Experience).
Answer: Any untoward medical occurrence in a patient or clinical
investigation subject administered a pharmaceutical product and which does
not necessarily have to have a causal relationship with this treatment.
◍ Elements of Protocol: Pharmacology and Pharmacokinetics.
Answer: Information about the ___________________ of the investigational
product, including its mechanism of action, absorption, distribution,
metabolism, and excretion.
,◍ Adverse Drug Reaction (ADR) in pre-approval.
Answer: All noxious and unintended responses to a medicinal product
related to any dose should be considered adverse drug reactions. The phrase
responses to a medicinal product means that a causal relationship between a
medicinal product and an adverse event is at least a reasonable possibility
◍ Elements of Protocol: Safety and Toxicology.
Answer: Summary of the ___________________ data from non-clinical
studies, including animal studies and any known adverse effects.
◍ Adverse Drug Reaction (ADR) in marketed medicinal products.
Answer: A response to a drug that is noxious and unintended and that occurs
at doses normally used in man for prophylaxis, diagnosis, or therapy of
diseases or for modification of physiological function
◍ Unexpected Adverse Drug Reaction.
Answer: An adverse reaction, the nature or severity of which is not
consistent with the applicable product information (e.g. Investigator's
Brochure for an unapproved investigational medicinal product)
◍ Difference between serious and severe.
Answer: The term "severe" is often used to describe the intensity (severity)
of a specific event; the event itself, however, may be of relatively minor
medical significance. This is not the same as "serious," which is based on
patient/event outcome or action criteria usually associated with events that
pose a threat to a patients life or functioning. Seriousness (not severity)
serves as a guide for defining regulatory reporting obligations.
◍ Serious Adverse Event (experience) or reaction.
Answer: Any untoward medicinal occurrence that at any dose: - results in
death - is life-threatening (pt. was a risk of death at the time of the event)-
requires inpatient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability/incapacity, or - is a congenital
anomaly/birth defect
◍ Expectedness of an Adverse Drug Reaction.
, Answer: The following documents or circumstances will be used to
determine whether an adverse event/reaction is expected: 1. For medicinal
product not yet approved for marketing in a country, a company's IB will
serve as the source document in that country 2. Reports which add
significant information in specificity or severity of a known, already
documented serious ADR constitute unexpected events. For example, an
event more specific or more severe than described in the IB would be
considered "unexpected."
◍ Elements of Protocol: Clinical Studies.
Answer: Summary of the ___________________ conducted with the
investigational product, including study design, patient populations, dosing
regimens, and safety and efficacy results.
◍ Single Cases of Serious, Unexpected ADRs.
Answer: All adverse drug reactions (ADRs) that are both serious and
unexpected aresubject to expedited reporting.
◍ Elements of Protocol: Regulatory Information.
Answer: Information about the ___________________ status of the
investigational product, including any regulatory approvals or submissions.
◍ Elements of Protocol: References.
Answer: List of ___________________ cited in the IB, including relevant
literature and regulatory documents.
◍ Elements of Protocol: Appendices.
Answer: Additional information that supports the content of the IB, such as
study protocols, case report forms, and patient information materials.
◍ Standards of Expedited Reporting - Other Observations.
Answer: There are situations in addition to single case reports of "serious"
adverse events or reactions that may necessitate rapid communication to
regulatory authorities; appropriate medical and scientific judgement should
be applied for each situation. In general, information that might materially
influence the benefit risk assessment of a medicinal product or that would be
2026 QUESTIONS WITH SOLUTIONS
GRADED A+
◍ Elements of Protocol: Title and Cover Page.
Answer: The title of the IB and any relevant cover page information, such as
the study name, sponsor, and version number.
◍ Elements of Protocol: Table of Contents.
Answer: A list of sections and subsections contained within the IB.
◍ Elements of Protocol: Introduction.
Answer: A brief overview of the investigational product, including its
purpose and background information.
◍ Elements of Protocol: Study Objectives and Protocol.
Answer: A description of the ___________________ and an overview of the
clinical trial ___________________ .
◍ Elements of Protocol: Investigational Product Description.
Answer: Detailed information about the investigational product, including
its chemical composition, formulation, packaging, and storage requirements.
◍ Adverse Event (or Adverse Experience).
Answer: Any untoward medical occurrence in a patient or clinical
investigation subject administered a pharmaceutical product and which does
not necessarily have to have a causal relationship with this treatment.
◍ Elements of Protocol: Pharmacology and Pharmacokinetics.
Answer: Information about the ___________________ of the investigational
product, including its mechanism of action, absorption, distribution,
metabolism, and excretion.
,◍ Adverse Drug Reaction (ADR) in pre-approval.
Answer: All noxious and unintended responses to a medicinal product
related to any dose should be considered adverse drug reactions. The phrase
responses to a medicinal product means that a causal relationship between a
medicinal product and an adverse event is at least a reasonable possibility
◍ Elements of Protocol: Safety and Toxicology.
Answer: Summary of the ___________________ data from non-clinical
studies, including animal studies and any known adverse effects.
◍ Adverse Drug Reaction (ADR) in marketed medicinal products.
Answer: A response to a drug that is noxious and unintended and that occurs
at doses normally used in man for prophylaxis, diagnosis, or therapy of
diseases or for modification of physiological function
◍ Unexpected Adverse Drug Reaction.
Answer: An adverse reaction, the nature or severity of which is not
consistent with the applicable product information (e.g. Investigator's
Brochure for an unapproved investigational medicinal product)
◍ Difference between serious and severe.
Answer: The term "severe" is often used to describe the intensity (severity)
of a specific event; the event itself, however, may be of relatively minor
medical significance. This is not the same as "serious," which is based on
patient/event outcome or action criteria usually associated with events that
pose a threat to a patients life or functioning. Seriousness (not severity)
serves as a guide for defining regulatory reporting obligations.
◍ Serious Adverse Event (experience) or reaction.
Answer: Any untoward medicinal occurrence that at any dose: - results in
death - is life-threatening (pt. was a risk of death at the time of the event)-
requires inpatient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability/incapacity, or - is a congenital
anomaly/birth defect
◍ Expectedness of an Adverse Drug Reaction.
, Answer: The following documents or circumstances will be used to
determine whether an adverse event/reaction is expected: 1. For medicinal
product not yet approved for marketing in a country, a company's IB will
serve as the source document in that country 2. Reports which add
significant information in specificity or severity of a known, already
documented serious ADR constitute unexpected events. For example, an
event more specific or more severe than described in the IB would be
considered "unexpected."
◍ Elements of Protocol: Clinical Studies.
Answer: Summary of the ___________________ conducted with the
investigational product, including study design, patient populations, dosing
regimens, and safety and efficacy results.
◍ Single Cases of Serious, Unexpected ADRs.
Answer: All adverse drug reactions (ADRs) that are both serious and
unexpected aresubject to expedited reporting.
◍ Elements of Protocol: Regulatory Information.
Answer: Information about the ___________________ status of the
investigational product, including any regulatory approvals or submissions.
◍ Elements of Protocol: References.
Answer: List of ___________________ cited in the IB, including relevant
literature and regulatory documents.
◍ Elements of Protocol: Appendices.
Answer: Additional information that supports the content of the IB, such as
study protocols, case report forms, and patient information materials.
◍ Standards of Expedited Reporting - Other Observations.
Answer: There are situations in addition to single case reports of "serious"
adverse events or reactions that may necessitate rapid communication to
regulatory authorities; appropriate medical and scientific judgement should
be applied for each situation. In general, information that might materially
influence the benefit risk assessment of a medicinal product or that would be
